Biocon Ltd
Ticker: BIOCON
Decent
66/100
☆ Add to Watchlist
Investing Reference
Price
356.40
Market Cap
47563.91
Debt/Equity
0.6626
ROE %
3.825
PB
1.7163
Promoter %
54.454
Pledge %
0.000
1Y Rev Growth %
6.051
5Y Rev Growth %
20.223
NP Margin %
6.117
NP Margin 5Y Avg %
6.877
Trading Reference
1M Return %
-3.814
6M Return %
8.378
1Y Return %
1.193
% Away 52W High
13.917
% Away 52W Low
22.474
Daily Volume
2332613
Investment Verdict
Buy
Score 75/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 29/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Biocon Ltd is currently trading near a key support level, with the 50-day EMA showing a bullish crossover with the 200-day EMA. If the stock maintains above this support, there is a potential for upward movement towards resistance levels. However, if it breaks below support, it could face further downside risk.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
L
Laurus Labs Ltd
Laurus Labs Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics.
View details
K
Kaynes Technology India Ltd
Kaynes Technology India Ltd shows potential for growth but faces challenges in profitability and valuation. Caution is advised for new investments.
View details
F
Federal Bank Ltd
Federal Bank Ltd shows decent potential but faces challenges in profitability and valuation metrics.
View details
U
United Breweries Ltd
United Breweries Ltd shows potential for growth, but faces challenges in profitability and valuation compared to peers.
View details
P
Premier Energies Ltd
Premier Energies Ltd has potential in a growing sector, but faces challenges in execution and profitability.
View details
A
APL Apollo Tubes Ltd
APL Apollo Tubes Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Investors should proceed with caution.
View details
G
GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd shows decent fundamentals but faces challenges in profitability and market sentiment. It is a stable player in a growing sector, but caution is advised due to valuation concerns and execution risks.
View details
A
Anthem Biosciences Ltd
Anthem Biosciences Ltd shows potential but faces challenges in growth consistency and profitability metrics.
View details
V
Voltas Ltd
Voltas Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
B
Balkrishna Industries Ltd
Balkrishna Industries Ltd shows a decent investment potential with strong fundamentals, but caution is advised due to valuation concerns and execution risks.
View details
H
Hexaware Technologies Ltd
Hexaware Technologies has a decent outlook with growth potential, but faces challenges in profitability and valuation metrics.
View details
T
Tata Communications Ltd
Tata Communications Ltd shows potential for growth but faces challenges in profitability and execution risks. It is a decent investment but requires careful monitoring.
View details
C
Cochin Shipyard Ltd
Cochin Shipyard Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
D
Dalmia Bharat Ltd
Dalmia Bharat Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
L
L&T Technology Services Ltd
L&T Technology Services Ltd shows decent potential with a strong focus on digital transformation, but faces challenges in profitability and valuation compared to peers.
View details
H
Housing and Urban Development Corporation Ltd
The stock presents a decent investment opportunity but comes with notable risks and challenges.
View details
Business Overview
Biocon Ltd is a leading biopharmaceutical company based in India, focused on developing innovative therapies for chronic conditions. Targeting patients with diabetes, cancer, and autoimmune diseases, Biocon plays a crucial role in enhancing healthcare accessibility. With a commitment to research and development, the company is at the forefront of biotechnology, making significant strides in affordable medicine. Biocon's expertise and dedication to quality make it a trusted partner in the global healthcare landscape.
- Leading biopharmaceutical company in India
- Focus on chronic diseases like diabetes and cancer
- Innovative therapies enhancing patient care
- Strong commitment to research and development
- Affordable medicine for broader accessibility
Investment Thesis
Biocon Ltd stands out as a compelling investment opportunity due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. The company's commitment to innovation and expanding market presence positions it well for future growth.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services, tapping into the evolving healthcare landscape.
- Attractive valuation metrics compared to industry peers, offering potential for upside.
- Focus on biosimilars and biopharmaceuticals aligns with global healthcare trends.
- Strong financial performance and consistent dividend payouts make it a reliable choice.
Opportunity vs Risk
Opportunities
- Strong pipeline of biosimilars
- Growing global healthcare demand
- Strategic partnerships with big pharma
- Expansion into new markets
Risks ⚠️
- Regulatory challenges in drug approvals
- Intense competition in biotech sector
- Currency fluctuations affecting profits
- Dependence on key product sales
Peer Perspective
Biocon Ltd trades at a discount compared to peers like Dr. Reddy's and Sun Pharma, primarily due to margin concerns. A focus on improving operational efficiencies could trigger a rerating, aligning growth with market expectations.
Future Outlook
Biocon Ltd is well-positioned for growth, driven by its robust pipeline and expanding global presence; however, successful execution and cost control will be critical to achieving its long-term objectives.
AI FAQs for Retail Users
- Q: What does Biocon Ltd do?A: Biocon Ltd is a biopharmaceutical company focused on developing and manufacturing innovative therapies.
- Q: Is Biocon Ltd a good investment?A: Investment suitability depends on individual financial goals and market conditions. Research thoroughly before investing.
- Q: What are Biocon's main products?A: Biocon's main products include insulin, biosimilars, and novel biologics for various diseases.
- Q: How has Biocon performed recently?A: Recent performance can vary. Check financial reports and market analyses for updated information.
- Q: What risks are associated with investing in Biocon?A: Risks include market volatility, regulatory changes, and competition in the biopharmaceutical sector.
📊 Stock Investment Checklist (100 Points)
Biocon Ltd • Updated: 2025-09-16 19:59:26
-
10BusinessHighBiocon operates in the biopharmaceutical sector, which is poised for growth due to increasing healthcare demands.
-
10GrowthHighThe company has shown consistent revenue growth, but profit margins have fluctuated.
-
10ProfitabilityHighROE and ROCE are moderate, with operating cash flow generally aligning with net profit.
-
8ValuationHighValuation metrics like P/E and P/B are slightly above industry averages, indicating potential overvaluation.
-
7BalanceHighThe balance sheet shows manageable debt levels, but liquidity could be improved.
-
6GovernanceGoodPromoter holding is strong, but there are concerns regarding pledging of shares.
-
5DriversGoodGrowth drivers include new product launches, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is mixed, with some recent volatility in stock price.
Final Score & Verdict
Score 66 / 100
• Decent
Biocon Ltd shows potential for growth in a promising sector, but faces challenges in profitability and valuation metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100